Iradimed (NASDAQ:IRMD) Updates Q4 2024 Earnings Guidance

by · The Cerbat Gem

Iradimed (NASDAQ:IRMD – Get Free Report) issued an update on its fourth quarter 2024 earnings guidance on Thursday morning. The company provided EPS guidance of 0.420-0.450 for the period, compared to the consensus EPS estimate of 0.400. The company issued revenue guidance of $18.8 million-$19.2 million, compared to the consensus revenue estimate of $19.3 million. Iradimed also updated its FY 2024 guidance to 1.640-1.670 EPS.

Iradimed Stock Down 2.0 %

NASDAQ IRMD traded down $0.97 during trading hours on Friday, hitting $48.30. 32,944 shares of the stock were exchanged, compared to its average volume of 28,110. The company has a market cap of $611.96 million, a price-to-earnings ratio of 33.08 and a beta of 0.79. Iradimed has a 12-month low of $39.24 and a 12-month high of $53.99. The stock has a 50-day moving average of $48.98 and a 200 day moving average of $45.56.

Iradimed (NASDAQ:IRMD – Get Free Report) last posted its quarterly earnings results on Thursday, August 1st. The medical equipment provider reported $0.38 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.33 by $0.05. The firm had revenue of $17.93 million during the quarter, compared to analysts’ expectations of $17.70 million. Iradimed had a net margin of 26.12% and a return on equity of 24.59%. During the same period in the prior year, the company posted $0.33 earnings per share. On average, equities research analysts expect that Iradimed will post 1.47 earnings per share for the current year.

Iradimed Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, November 25th. Investors of record on Friday, November 15th will be issued a dividend of $0.15 per share. The ex-dividend date is Friday, November 15th. This represents a $0.60 annualized dividend and a yield of 1.24%. Iradimed’s dividend payout ratio is currently 41.10%.

Analyst Ratings Changes

Separately, Roth Mkm cut their price target on shares of Iradimed from $65.00 to $60.00 and set a “buy” rating for the company in a report on Friday, August 2nd.

Get Our Latest Stock Analysis on Iradimed

About Iradimed

(Get Free Report)

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices and related accessories, and disposables and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; MRI compatible patient vital signs monitoring system; and 3600 FMD1 with RALU ferromagnetic detection device.

Recommended Stories